ERBB2 and breast carcinoma: Similarly, ephrin-B2 expression is associated with the clinically aggressive basal-like breast cancer subtype and HER2(+) tumors [33], while its overexpression is associated with the presence of LN metastasis, HER2 positivity, and the triple-negative breast cancer subtype [34].